- Your Visit
- Welcome to Capital Health
- Your Healthcare Team
- Patient Satisfaction
- Telephone Directory
- Guest Relations
- Mission and Vision
- Confidentiality
- Accommodations
- In-Room Services
- Infection Control
- Nutrition
- Special Services
- Patient Safety
- Friends and Family
- Going Home
- Bills and Insurance
- Keeping Healthy
- Patient Responsibility
- Patient Rights
- Speak Up For Safety
- Patient Services
- Cardiology
- Corporate Health Center
- Corporate Rehabilitation
- Early Intervention Services
- Fitness and Rehabilitation
- Guest Relations
- Integral Medicine
- Lactation Center
- Neurophysiology Laboratory
- Nutrition Services
- Orthopaedic Surgery
- Pastoral Care
- Pharmacy Services
- Pulmonary Rehabilitation
- Rehabilitation Services
- Renal Dialysis Services
- Speech Pathology
- Stroke Alert
- Vascular Services
- Wound Management
- Educational Services
- News
- Find a Physician
- Contact Us
 |
Capital Health News
See All News
Printer Friendly 
Email a FriendCyberKnife® Center Enters Multi-Center Research Study for Treatment of Patients with Resected Metastatic Brain Tumors
March 11, 2010The Capital Health CyberKnife Center recently announced a research study to determine the effectiveness of CyberKnife® stereotactic radiosurgery on patients with resected metastatic brain cancer. The trial is a multi-center study being done in collaboration with the Community Cancer Center in Normal, IL.
Capital Health is the only hospital in the tri-state area approved for participation in this national study.
Recent treatment guidelines from the National Comprehensive Cancer Network suggest surgical resection of relatively large metastatic brain lesions followed by external beam radiation therapy is the most effective means by which to control the spread of cancer within the brain. However, because the radiation can destroy nearby healthy brain tissue along with cancer cells, this treatment model still presents a potential danger to the patient. Exposing the whole brain to radiation has been associated with cognitive deficits that can affect learning, memory, personality, and intelligence quotient (or IQ).
The purpose of this new research study is to evaluate a potential novel treatment combination (surgery followed by CyberKnife radiosurgery treatment) for metastatic brain tumors.
“Through this study, we hope to discover improved treatment options that result in better tumor control without the serious side effects associated with traditional radiation therapy,” said Dr. John Lipani, surgical director of CyberKnife Radiosurgery and director of Neurosurgical Oncology who is serving as a sub-investigator on the study.
In addition to Dr. Lipani, Dr. Shirnett Williamson, director of Radiation Oncology Services, is also a sub-investigator on the study. Derrick Grant, PhD, CyberKnife clinical doctoral research coordinator is the coordinator for the study’s implementation at Capital Health.
This study is being done in collaboration with Dr. Don Stacy, who heads the CyberKnife program at the Community Cancer Center in Normal, IL.
Capital Health’s CyberKnife Center is expecting to enroll 20 patients in this brain metastasis protocol over the period of one year. Patients who enroll must have undergone initial surgery to remove from one to three metastatic brain tumors. After consenting to participate in the study, patients will be asked to undergo a history and physical examination to evaluate their candidacy for the trial.
For more information on the CyberKnife study, call the Capital Health CyberKnife Center’s research office at 609-394-4503.